Bacteriocin-mediated inhibition of some common pathogens by wild and mutant Lactobacillus species and in vitro amplification of bacteriocin encoding genes

Biotechnological potential of Lacticaseibacillus paracasei Shirota for bioemulsifier, bacteriocin and lipase production

This study aimed to evaluate the biotechnological potential of Lacticaseibacillus paracasei Shirota to produce biosurfactants/bioemulsifiers, lipase, and bacteriocins. The production of biosurfactants/bioemulsifiers was evaluated through a central composite rotational design (CCRD) 22. L. paracasei produced bioemulsifiers using MRS supplemented with 4.8% glycerol and pH 6 or 7. In addition, the culture supernatants of L. paracasei were tested for antioxidant, antidiabetic, and lipolytic activities. The tested supernatants did not exhibit antioxidant activity. On the other hand, they showed inhibitory activity for amyloglucosidase (20.7% and 23.9%) and lipolytic activity (16.12 and 19.00 U/mL). In addition, a CCRD 23 was performed to evaluate the production of bacteriocins. The peptone and lactose concentration variables, as well as pH positively influenced the production of bacteriocins by L. paracasei. In conclusion, L. paracasei is a viable source of antidiabetic metabolites, bacteriocins, bioemulsifiers, and lipase, suggesting that they are promising to be applied in the pharmaceutical, cosmetic, environmental, food, and biomedical industries.

Gut microbiome and human health: Exploring how the probiotic genus Lactobacillus modulate immune responses

The highest density of microbes resides in human gastrointestinal tract, known as “Gut microbiome”. Of note, the members of the genus Lactobacillus that belong to phyla Firmicutes are the most important probiotic bacteria of the gut microbiome. These gut-residing Lactobacillus species not only communicate with each other but also with the gut epithelial lining to balance the gut barrier integrity, mucosal barrier defence and ameliorate the host immune responses. The human body suffers from several inflammatory diseases affecting the gut, lungs, heart, bone or neural tissues. Mounting evidence supports the significant role of Lactobacillus spp. and their components (such as metabolites, peptidoglycans, and/or surface proteins) in modulatingimmune responses, primarily through exchange of immunological signals between gastrointestinal tract and distant organs. This bidirectional crosstalk which is mediated by Lactobacillus spp. promotes anti-inflammatory response, thereby supporting the improvement of symptoms pertaining to asthma, chronic obstructive pulmonary disease (COPD), neuroinflammatory diseases (such as multiple sclerosis, alzheimer’s disease, parkinson’s disease), cardiovascular diseases, inflammatory bowel disease (IBD) and chronic infections in patients. The metabolic disorders, obesity and diabetes are characterized by a low-grade inflammation. Genus Lactobacillus alleviates metabolic disorders by regulating the oxidative stress response and inflammatory pathways. Osteoporosis is also associated with bone inflammation and resorption. The Lactobacillus spp. and their metabolites act as powerful immune cell controllers and exhibit a regulatory role in bone resorption and formation, supporting bone health. Thus, this review demonstrated the mechanisms and summarized the evidence of the benefit of Lactobacillus spp. in alleviating inflammatory diseases pertaining to different organs from animal and clinical trials. The present narrative review explores in detail the complex interactions between the gut-dwelling Lactobacillus spp. and the immune components in distant organs to promote host’s health.

Anti-Campylobacter Probiotics: Latest Mechanistic Insights

The Campylobacter genus is the leading cause of human gastroenteritis, with the consumption of contaminated poultry meat as the main route of infection. Probiotic bacteria, such as Lactobacillus, Bacillus, Escherichia coli Nissle, and Bifidobacterium species, have a great immunomodulatory capacity and exhibit antipathogenic effects through various molecular mechanisms. Reducing Campylobacter levels in livestock animals, such as poultry, will have a substantial benefit to humans as it will reduce disease transmissibility through the food chain. Moreover, probiotic-based strategies might attenuate intestinal inflammatory processes, which consequently reduce the severity of Campylobacter disease progression. At a molecular level, probiotics can also negatively impact on the functionality of various Campylobacter virulence and survival factors (e.g., adhesion, invasion), and on the associated colonization proteins involved in epithelial translocation. The current review describes recent in vitro, in vivo, and preclinical findings on probiotic therapies, aiming to reduce Campylobacter counts in poultry and reduce the pathogen's virulence in the avian and human host. Moreover, we focused in particular on probiotics with known anti-Campylobacter activity seeking to understand the biological mechanisms involved in their mode of action.